Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
328.81
+0.81 (0.25%)
At close: Jul 25, 2025, 4:00 PM
328.81
0.00 (0.00%)
After-hours: Jul 25, 2025, 4:53 PM EDT
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $594.19M in the quarter ending March 31, 2025, with 20.20% growth. This brings the company's revenue in the last twelve months to $2.35B, up 17.21% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.
Revenue (ttm)
$2.35B
Revenue Growth
+17.21%
P/S Ratio
17.95
Revenue / Employee
$1,052,959
Employees
2,230
Market Cap
42.87B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ALNY News
- 2 days ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 8 days ago - Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results - Business Wire
- 24 days ago - Alnylam Pharma Stock Outlook: Is ALNY Topping Out? - Benzinga
- 5 weeks ago - Alnylam Pharmaceuticals Names Garg R&D Chief - Market Watch
- 5 weeks ago - Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire
- 6 weeks ago - Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 2 months ago - Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - Business Wire
- 2 months ago - Alnylam Issues 2024 Corporate Responsibility Report - Business Wire